Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report

Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors. Therefore, HIF-PH inhibitors may exacerbate retinal hemorrhage in diseases such as diabetic reti...

Full description

Bibliographic Details
Main Authors:	Nobuaki Ariyoshi, Fumiaki Higashijima, Makiko Wakuta, Tadahiko Ogata, Manami Ohta, Kazuhiro Kimura
Format:	Article
Language:	English
Published:	Karger Publishers 2024-03-01
Series:	Case Reports in Ophthalmology
Subjects:	hypoxia-inducible factor-prolyl hydroxylase inhibitor vascular endothelial growth factor diabetic retinopathy renal anemia
Online Access:	https://beta.karger.com/Article/FullText/537913

Similar Items

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020-07-01)

Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats
by: Anqi Zhang, et al.
Published: (2021-06-01)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
by: Matthew E Cockman, et al.
Published: (2019-09-01)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023-05-01)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)

Structural Characterization of Hypoxia Inducible Factor α—Prolyl Hydroxylase Domain 2 Interaction through MD Simulations
by: Giorgia F. Camagni, et al.
Published: (2023-03-01)

Role of prolyl hydroxylase domain proteins in bone metabolism
by: David Wolf, et al.
Published: (2022-03-01)

Prolyl Hydroxylase 3 Knockdown Accelerates <i>VHL</i>-Mutant Kidney Cancer Growth In Vivo
by: Niki M. Zacharias, et al.
Published: (2021-03-01)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022-09-01)

Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice
by: Shunji Nishide, et al.
Published: (2020-06-01)

An Arabidopsis Prolyl 4 Hydroxylase Is Involved in the Low Oxygen Response
by: Anna Konkina, et al.
Published: (2021-03-01)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
by: So Yeon Kim, et al.
Published: (2015-11-01)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
by: Chintala Sreenivasulu, et al.
Published: (2012-07-01)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023-11-01)

Prolyl Hydroxylase Domain-Containing Protein 3 Gene Expression in Chondrocytes Is Not Essential for Bone Development in Mice
by: Weirong Xing, et al.
Published: (2021-08-01)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
by: Hanxue Zhao, et al.
Published: (2023-12-01)

HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
by: Andrew N. Billin, et al.
Published: (2018-11-01)

Prolyl Hydroxylase Domain-2 Inhibition Improves Skeletal Muscle Regeneration in a Male Murine Model of Obesity
by: Indranil Sinha, et al.
Published: (2017-07-01)

Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia
by: Qianqian Ruan, et al.
Published: (2024-04-01)

Network activity in primary hippocampal cultures upon HIF-prolyl hydroxylase inhibition
by: Savyuk, Maria Olegovna, et al.
Published: (2021-05-01)

The effects of prolyl hydroxylase inhibition during and post, hypoxia, oxygen glucose deprivation and oxidative stress, in isolated rat hippocampal slices
by: Niamh Moreton, et al.
Published: (2023-12-01)

Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis
by: Paola Pignata, et al.
Published: (2021-04-01)

Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors
by: Akira Takahashi
Published: (2024-02-01)

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
by: Junlan Yang, et al.
Published: (2023-03-01)

L-mimosine and hypoxia can increase angiogenin production in dental pulp-derived cells
by: Klara Janjić, et al.
Published: (2017-05-01)

Prolyl Hydroxylase Paralogs in Nicotiana benthamiana Show High Similarity With Regard to Substrate Specificity
by: Réka Mócsai, et al.
Published: (2021-03-01)

Suppression of a Prolyl 4 Hydroxylase Results in Delayed Abscission of Overripe Tomato Fruits
by: Andreas Perrakis, et al.
Published: (2019-03-01)

Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study
by: Kimio Watanabe, et al.
Published: (2023-08-01)

Cycloheximide promotes type I collagen maturation mainly via collagen prolyl 4-hydroxylase subunit α2
by: Shi Run, et al.
Published: (2022-12-01)

Whole-Body Prolyl Hydroxylase Domain (PHD) 3 Deficiency Increased Plasma Lipids and Hematocrit Without Impacting Plaque Size in Low-Density Lipoprotein Receptor Knockout Mice
by: Jasper A. F. Demandt, et al.
Published: (2021-05-01)

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
by: Qiyan Zheng, et al.
Published: (2023-04-01)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023-05-01)

Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases
by: Satoshi Yamasaki, et al.
Published: (2023-03-01)

Long-Term Environmental Hypoxia Exposure and Haematopoietic Prolyl Hydroxylase-1 Deletion Do Not Impact Experimental Crohn’s Like Ileitis
by: Cara De Galan, et al.
Published: (2021-09-01)

High Glucose Activates Prolyl Hydroxylases and Disrupts HIF-α Signaling via the P53/TIGAR Pathway in Cardiomyocyte
by: Jian-Xiong Chen, et al.
Published: (2023-03-01)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023-06-01)

miR‐17/20 Controls Prolyl Hydroxylase 2 (PHD2)/Hypoxia‐Inducible Factor 1 (HIF1) to Regulate Pulmonary Artery Smooth Muscle Cell Proliferation
by: Tianji Chen, et al.
Published: (2016-12-01)

Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients
by: Dechao Feng, et al.
Published: (2023-07-01)

MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia
by: Courtney A Copeland, et al.
Published: (2023-07-01)

Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
by: Moritz J. Strowitzki, et al.
Published: (2019-04-01)